Hit the inbox at 8:02AM this morning....
from Paragon:
“I see ARTH as one of the best finds of my career, a potential blockbuster for shareholders as well as being a top-tier medical breakthrough that could one day save your life.” – Analyst Ian Cooper
Members,
Respected analyst Ian Cooper has spent the better part of the last decade mastering the art of trading options for triple-digit gains, avoiding the "herd mentality" of Wall Street. He has shown thousands of investors exactly how to exploit carefully targeted market sectors for lightning-fast short-term gains. Just this week, Ian Cooper has issued his new “Speed Retirement System” report highlighting the New Technologies Revolution. In this report, he focuses on Arch Therapeutics (ARTH) as his stock to follow this year. Below is an excerpt from his Summer 2013 Special Report:
Ian Cooper’s Speed Retirement System, Special Report, Summer 2013:
“This may be the most important medical discovery in decades and it could earn you a fortune!
To the Informed Investor:
Medical breakthroughs often become huge moneymakers for ground-floor shareholders, but nothing I've seen in recent memory is as far-reaching as this. The stock I recommend for immediate consideration is Arch Therapeutics (ARTH). Within months, Arch Therapeutics could become the most talked about medical company on the planet and its stock, ARTH, could be selling three- to five-times what you can get in for today. The reason is simple:
Arch Therapeutics is preparing to release a ground-breaking new medical product that could benefit the entire global population.
Yes, I mean everyone, over seven billion people in a market exceeding 32 billion dollars!
This revolutionary medical product, called AC5™, is reported to do one thing better than anything else on the market today.... When applied to an incision or wound, AC5™ stops the bleeding and seals the wound almost instantly.
When you look at the global reach and numbers for AC5™, it could be the fastest growing medical product to be introduced in decades!
Bleeding is a fact of life, yet despite all the medical advances made in our lifetimes, bleeding control has stayed largely unchanged for over 100 years. Recently however, researchers at the Massachusetts Institute of Technology (MIT) developed a breakthrough for bleeding control. One noted surgeon calls AC5™ the “Holy Grail”. Another calls it a“gamechanger” that he would use in “80 percent of my cases.”
Clinical tests conclusively show that AC5™ stops blood flow in seconds rather than minutes... up to 30-times faster in many applications!
From an investor’s point-of-view, ARTH is one of the best growth opportunities I’ve seen in years; I urge you to act on this immediately!
This is a pivotal time for investors to move on ARTH. From here on in...
All progress to market amplifies ARTH growth potential.
Every announcement carries significant potential for share price gains.
By the end of the year, ARTH could be a 3.00 to 5.00 dollar stock and climbing.
Longer term, ARTH could be a 20 dollar stock or better either through global market gains or acquisition by a major such as Johnson and Johnson, maker of Band-Aid® products.
The lengthy research and development phase is complete; Arch Therapeutics now enters the final phases that lead to market release. Closing in fast, this opportunity is one to act on immediately.
In my view, this is a slam-dunk for biotech investing.
An urgent investment opportunity
This is such a revolutionary product, a real game-changer, that news of AC5™ and Arch Therapeutics could spread like wildfire through medical and investment communities. If you are thinking of getting ARTH into your portfolio at today’s bargain price, then make your move immediately. These may be the final moments of ARTH as a ground-floor investment.
As soon as investors get wind of this, I anticipate a flood of buying that could get started at any time now. Currently trading around one dollar, the short-term potential for ARTH to hit the 3.00 to 5.00 dollar mark can be driven by a cascade of post-R&D developments.
ARTH has buy out potential written all over it!
My guess is that someone big is going to take ARTH out, paying an enormous premium to own this exciting new technology. Top of my acquisition prospect list is Johnson & Johnson (JNJ). AC5™ has the potential to demolish JNJ sales in its wound-care products. This includes its heritage brand, Band-Aid, which along with all its products in consumer wound care category generated $1 billion in sales for JNJ last year.
My conclusion is that AC5™, once released to the medical world, can rapidly reduce the risk and expense of bleeding management and greatly improve patient outcomes. As an investment, I rarely see an opportunity this good!”
Read Ian Cooper’s Complete Analysis of ARTH – Select Here to read the full Report
Members, you heard it here first! Respected analyst Ian Cooper has just released his Summer 2013 “Speed Retirement System” Report highlighting our featured company Arch Therapeutics (ARTH). We encourage all of you to read his full report now by selecting the link above. If you have not done so already, now is the time to research ARTH before its share price potentially skyrockets to Ian Cooper’s short-term price target of 3.00 dollars. Do not delay, research ARTH now! www.archtherapeutics.com
Sincerely,
The Paragon Team
